« Back
Home /
Ibandronic acid

Ibandronic acid

Item no.	HY-B0515A-1ea
Manufacturer	MedChem Express
CASRN	114084-78-5
Amount	1 ea
Category	Reagents & Chemicals Biochemicals
Type	Chemicals
Specific against	other
Formula	C9H23NO7P2
Citations	[1]Morgan, C., S. Jeremiah, and J. Wagstaff, Metronomic administration of ibandronate and its anti-angiogenic effects in vitro. Microvasc Res, 2009. 78(3): p. 453-8.<br>[2]Epplen, R., et al., Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines. Acta Oncol, 2011. 50(1): p. 127-33.<br>[3]Chesnut, I.C., et al., Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res, 2004. 19(8): p. 1241-9.<br>[4]Bauss, F., et al., Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J Rheumatol, 2002. 29(10): p. 2200-8.
Smiles	OC(P(O)(O)=O)(P(O)(O)=O)CCN(C)CCCCC
ECLASS 10.1	32160000
ECLASS 11.0	32160000
UNSPSC	12000000
Available
Shipping	Room temperature
Manufacturers Applications	Cancer-programmed cell death
MolecularWeight	319.23
Clinical_Information	Launched
Manufacturers Research_Area	Cancer
Solubility	10 mM in DMSO
Manufacturers Target	Others
Pathway	Others
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 1 ea

available

Request delivery time